摘要
原发性纵隔大B细胞淋巴瘤(PMBL)具有独特的临床病理和生物学特点。研究发现其某些分子特征与结节性硬化霍奇金淋巴瘤(NSHL)相似。最近的研究不仅关注这两种肿瘤的共同生物学特点,确定了淋巴瘤形成的新的关键途径,还关注它们不同的突变基因。虽然目前PMBL的标准治疗方法是化疗和放疗,但也提出了去除放疗以消除其长期毒副作用的方法。在PMBL中评估新的靶向药物的作用和影响,为研究小分子抑制剂和免疫检查点抑制剂等药物铺平了道路,并指明这些疾病的未来治疗方向应侧重于有效的新药与化疗相结合。
Primary mediastinal large B-cell lymphoma(PMBL)has unique clinical clinicopathological and biological characteristics.Studies have found that certain molecular features are similar to nodular sclerosis Hodgkin lymphoma(NSHL).Recent researches have focused not only on the common biological characteristics of these two tumors,but also on the identification of new key pathways for lymphoma formation,as well as their different mutant genes.Although the current standard of treatment for PMBL is chemotherapy and radiation therapy,methods are also proposed to eliminate radiation and thereby eliminate its long-term toxic effects.The role and impact of new targeted drug have been evaluated in PMBL,paving the way for testing drugs such as small molecule inhibitors and immunological checkpoint inhibitors,and indicating that future treatments should focus on combining effective new drugs with chemotherapy.
作者
袁婷
曹铮
冯晓莉
YUAN Ting;CAO Zheng;FENG Xiaoli(Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《肿瘤防治研究》
CAS
CSCD
2020年第5期387-392,共6页
Cancer Research on Prevention and Treatment
